NOVAVAX INC (NVAX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, NOVAVAX INC reported revenue of $1.12B, up 64.7% from the prior year. The company was profitable, with a net margin of 39.2%. It held $1.18B in total assets against $1.30B in total liabilities.
Key ratios (FY2025)
40.3%
Operating margin
39.2%
Net margin
+64.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $682.16M | $983.71M | $1.98B | $1.15B | $475.60M | $18.66M | $34.29M | $31.18M | $15.35M |
| Cost of Revenue | $73.04M | $202.74M | $343.77M | $902.64M | $0 | $0 | — | — | — | — |
| Operating Income | $452.80M | -$248.93M | -$566.51M | -$644.74M | -$1.69B | -$416.72M | -$120.58M | -$173.92M | -$171.71M | -$269.11M |
| Net Income | $440.30M | -$187.50M | -$545.06M | -$657.94M | -$1.74B | -$418.26M | -$132.69M | -$184.75M | -$183.77M | -$279.97M |
| EPS (Diluted) | $2.58 | $-1.23 | $-5.41 | $-8.42 | $-23.44 | $-7.27 | $-5.51 | — | — | — |
| Total Assets | $1.18B | $1.56B | $1.80B | $2.26B | $2.58B | $1.58B | $172.96M | $207.98M | $302.49M | $394.30M |
| Total Liabilities | $1.30B | $2.18B | $2.51B | $2.89B | $2.93B | $955.27M | $358.97M | $375.91M | $404.23M | $399.85M |
| Shareholders' Equity | -$127.75M | -$623.84M | -$716.93M | -$634.08M | -$351.67M | $627.21M | -$186.02M | -$167.94M | -$101.73M | -$5.55M |
| Cash & Equivalents | $240.63M | $530.23M | $568.50M | $1.34B | $1.52B | $553.40M | $78.82M | $70.15M | $106.31M | $144.35M |
| Operating Cash Flow | -$244.63M | -$87.26M | -$713.97M | -$415.94M | $322.95M | -$42.54M | -$136.62M | -$184.82M | -$144.48M | -$258.77M |
| Capital Expenditures | — | — | — | — | $57.49M | $54.62M | $1.86M | $1.37M | $4.19M | $18.20M |
| Shares Outstanding | 162.58M | 160.42M | 139.51M | 86.04M | 75.84M | 70.95M | 32.35M | 19.22M | 323.23M | 271.25M |